D-1 dopamine receptors and the topography of unconditioned motor behaviour: studies with the selective, 'full efficacy' benzazepine D-1 agonist SKF 83189
- PMID: 22291242
- DOI: 10.1177/026988119200600111
D-1 dopamine receptors and the topography of unconditioned motor behaviour: studies with the selective, 'full efficacy' benzazepine D-1 agonist SKF 83189
Abstract
Approaches to studying the role of the D-1 receptor in the regulation of unconditioned motor behaviour, and the current status of results derived therefrom, are reviewed; the desirability of utilizing drug tools other than the benzazepine partial D-1 agonist SKF 38393 is emphasized, particularly the need for studies with full D-1 agonists. Behavioural responses to the benzazepine putative full D-1 agonist SKF 83189 were compared with those to its high potency but only partial agonist counterpart SKF 77434. Both agents produced qualitatively and generally quantitatively similar behavioural responses, particularly intense grooming in the absence of vacuous chewing; thus, their behavioural properties appeared entirely unrelated to their efficacies to stimulate adenylate cyclase, the classical definition of a D-1 agonist. There may be complex interactions between selectivity, intrinsic activity and CNS penetrability, or a high D-1 receptor reserve ('spare' receptors); however, these results point towards the notion of behaviourally relevant subtypes of D-1 receptor, possibly utilizing transduction mechanisms other than, or additional to, adenylyl cyclase, for which there is emerging evidence.
Similar articles
-
SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography.Eur J Pharmacol. 2004 Feb 23;486(3):273-80. doi: 10.1016/j.ejphar.2004.01.004. Eur J Pharmacol. 2004. PMID: 14985049
-
Effects of full D1 dopamine receptor agonists on firing rates in the globus pallidus and substantia nigra pars compacta in vivo: tests for D1 receptor selectivity and comparisons to the partial agonist SKF 38393.J Pharmacol Exp Ther. 1998 Jul;286(1):272-81. J Pharmacol Exp Ther. 1998. PMID: 9655869
-
A comparison of the locomotor stimulant effects of D1-like receptor agonists in mice.Pharmacol Biochem Behav. 2005 Aug;81(4):843-8. doi: 10.1016/j.pbb.2005.06.006. Pharmacol Biochem Behav. 2005. PMID: 16000217
-
Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.J Pharmacol Exp Ther. 1997 Oct;283(1):7-15. J Pharmacol Exp Ther. 1997. PMID: 9336302
-
The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.Eur J Pharmacol. 2005 Dec 28;528(1-3):88-94. doi: 10.1016/j.ejphar.2005.11.003. Epub 2005 Dec 1. Eur J Pharmacol. 2005. PMID: 16324697
Cited by
-
Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.Psychopharmacology (Berl). 1995 Feb;117(4):403-12. doi: 10.1007/BF02246211. Psychopharmacology (Berl). 1995. PMID: 7604140
-
Behavioral effects of the R-(+)- and S-(-)-enantiomers of the dopamine D(1)-like partial receptor agonist SKF 83959 in monkeys.Eur J Pharmacol. 2007 Mar 8;558(1-3):98-106. doi: 10.1016/j.ejphar.2006.11.042. Epub 2006 Dec 1. Eur J Pharmacol. 2007. PMID: 17207791 Free PMC article.
-
Behavioural evidence for "D-1-like" dopamine receptor subtypes in rat brain using the new isochroman agonist A 68930 and isoquinoline antagonist BW 737C.Psychopharmacology (Berl). 1993;113(1):45-50. doi: 10.1007/BF02244332. Psychopharmacology (Berl). 1993. PMID: 7862827
-
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.Psychopharmacology (Berl). 1995 Feb;117(3):275-86. doi: 10.1007/BF02246102. Psychopharmacology (Berl). 1995. PMID: 7770603
-
The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.Psychopharmacology (Berl). 1995 Feb;117(3):287-97. doi: 10.1007/BF02246103. Psychopharmacology (Berl). 1995. PMID: 7770604
LinkOut - more resources
Full Text Sources